Nippon Shinyaku Selects LifeSphere® Safety
Japan-based Nippon Shinyaku has chosen LifeSphere MultiVigilance as new case processing database TOKYO, Oct. 28, 2025 /PRNewswire/ -- ArisGlobal, an AI-first technology company at the forefront of life sciences and creator of LifeSphere®, today announced that Nippon Shinyaku, Ltd. has selected its LifeSphere® Safety platform. Nippon Shinyaku sought a global single database...
Vietnam Healthcare Summit 2025: Powering Transformation of Vietnam’s Healthcare Landscape Through Innovation and Investment
HO CHI MINH CITY, Vietnam, Oct. 28, 2025 /PRNewswire/ -- Vietnam Innovators Digest successfully hosted the Vietnam Healthcare Summit 2025 under the theme "Making Vietnam an Innovation Hub Through Healthcare", held at JW Marriott Hotel & Suites Saigon. The event gathered over 200 healthcare leaders, investors, policymakers, and experts both domestically and internationally, to engage in strategic dialogue on Vietnam's...
Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics
Acquisition expands U.S. lab operations and accelerates innovation in non-invasive diagnostics for metabolic and liver diseases. NEW ORLEANS, Oct. 27, 2025 /PRNewswire/ -- Fibronostics, a global leader in non-invasive diagnostics for metabolic and liver diseases, today announced the completion of its acquisition of Stone Clinical Laboratories, LLC, a leading provider of advanced...
The WEMP Foundation and Rafa Nadal Foundation are joining together to Support Total Wellbeing of Children and Youth through Play
HONG KONG, Oct. 27, 2025 /PRNewswire/ -- The WEMP Foundation (WEMP, which stands for "Wellbeing", "EQ", "Mental Health", and "Parenting") and the Rafal Nadal Foundation (RNF) are delighted to announce their alliance for supporting total wellbeing of children and youth around the world through Play. Dr. Adrian Cheng, founder of The WEMP Foundation, and Mr. Rafael Nadal, founding patron of the...
Shanton Pharma Completes EOP2 Meeting with US FDA for Refractory Gout Program
SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., Oct. 27, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech developing a novel treatment for gout, today announced the successful completion of an End-of-Phase 2 meeting with US FDA for its Investigational New Drug...
BioDlink Completes First International Shipment of Bevacizumab to Colombia
Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death in Colombia. This inaugural shipment—dispatched around two months after Colombia's marketing approval—demonstrates the company's efficiency, while validating its antibody commercialization platform, as well as robust production quality and supply...
Kolmar Korea Selected for Government-Led ‘AI Factory’ Initiative — Driving Innovation in K-Beauty Manufacturing
The only cosmetics company chosen by the Ministry of Trade, Industry and Resources for the "AI Factory" project Enables agile, small-batch, multi-product production to meet diverse client needs in real time SEOUL, South Korea, Oct. 27, 2025 /PRNewswire/ -- Kolmar Korea announced that it has been selected as the sole...
National Center of Technology Innovation for Dairy Debuts at the IDF World Dairy Summit, Showcasing Innovation to Drive Sustainability
SANTIAGO, Chile, Oct. 27, 2025 /PRNewswire/ -- The highly anticipated 2025 IDF World Dairy Summit took place from October 20 to 23 in Santiago, Chile. Drawing global attention, the event served as an important barometer for the future of the dairy industry. Liu Chunxi, Chairman of the National Center of Technology Innovation for Dairy (NCTID) and Senior Executive President of...
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
SYDNEY, Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration (FDA) to discuss overall survival (OS) findings in newly diagnosed glioblastoma (GBM) patients treated with paxalisib and to seek agency feedback on a potential regulatory pathway...
Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial
Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study 94 patients enrolled out of 102 planned across Korea and the U.S. Interim baseline characteristics to be presented at the 2025 KATRD International Conference SEOUL, South Korea, Oct. 27, 2025 /PRNewswire/ -- Daewoong Pharmaceutical...
